Travere Therapeutics' market cap has more than doubled in six months, reflecting confidence in FILSPARI's role in treating ...

Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, ...

In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from ...

A new FDA approval for a first-in-class drug has vaulted Otsuka into immunoglobulin A nephropathy (IgAN), an increasingly competitive kidney disease field targeted by multiple biopharma companies.

Rio Tinto Group is planning to sell its US boron assets, which could be valued at up to $2 billion, according to a Bloomberg report on Wednesday.

Anti-APRIL antibody Voyxact (sibeprenlimab) has been approved by the US regulator to reduce proteinuria in adults with ...

Sanofi stock dropped Wednesday after French authorities raided the drugmaker's Paris headquarters as part of a tax fraud ...